USPTO 2015–2025 USPTO PatentsView US Corporation

Janssen Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 769 granted patents across 46 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Janssen ranks #584 of 49,997 tracked US assignees by granted-patent volume, with 769 patents across 46 technology areas.

#584
of 49,997 US assignees by volume
Top 2%
by Innovation Score (63.4/100)
17.3
avg claims per patent
-7%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R584 · US Corporation #584 · 769 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-USCORP · VEL-FLAT · BOOK-FULL

  • GRANTS-MID 769 grants
  • TOP-DECILE #584/49,997
  • PHOTO-FINISH Axis AB
  • CPC-WIDE A61P · 46 areas
  • INNOV-STRONG 63.4/100
  • CLAIMS-RICH 17.3 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-FLAT -7% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Axis AB (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Janssen

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Janssen's Innovation Score is 63.4/100 (top 2% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Janssen's grants concentrate

Janssen Pharmaceuticals, Inc. is a focused PatentsView assignee: 46 CPC subclasses with 77% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (95 grants) versus a trough of 63 in 2019. By volume, Janssen sits between Hitachi Construction Machinery Co., Ltd. and MediaTek Singapore Pte. Ltd..

Janssen's three-year grant acceleration

From 2019–2021 to 2022–2024, Janssen Pharmaceuticals, Inc. moved from 215 to 197 grants (0.92x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,423. See the growth leaderboard.

Who files at Janssen's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Janssen holds 769 patents at rank #584, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Janssen

By rank, the assignees closest to #584 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Janssen's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Janssen, neither rank-band nor same-CPC leaders (those blocks stay above).

Janssen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

63 Top 2% higher than 98% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

406080100 20152016201720182019202020212022202320242025 43
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Janssen Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 95 12.4%
2016 72 9.4%
2017 76 9.9%
2018 71 9.2%
2019 63 8.2%
2020 78 10.1%
2021 74 9.6%
2022 65 8.5%
2023 67 8.7%
2024 65 8.5%
2025partial year 43 5.6%

Which technologies does Janssen Pharmaceuticals, Inc. patent most?

Top 15 of 46 technology areas

Where it ranks

Overall rank by patents

#584

of 49,997 tracked assignees

Innovation Score

63.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Janssen Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

  • Janssen Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 77% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #584 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Janssen Pharmaceuticals, Inc. against Hitachi Construction Machinery Co., Ltd., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 63.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.